New Drug Combination Shows Promise for T-Cell Lymphoma Treatment
A groundbreaking study reveals that the combination of duvelisib and romidepsin offers a safe and effective treatment for relapsed T-cell lymphomas, improving patient outcomes and eligibility for stem cell transplants.
Relapsed or refractory peripheral and cutaneous T-cell lymphomas (R/R PTCL and CTCL) are aggressive forms of blood cancers that often do not respond to standard treatments. Patients with these lymphomas typically require stem cell transplants to potentially cure the disease; however, controlling the disease beforehand is crucial for successful transplantation.
A recent study led by researchers from the PETAL Consortium at Mass General Brigham investigated a novel drug combination involving duvelisib and romidepsin. The findings demonstrated that this combination is effective, well-tolerated, and safe for patients battling R/R PTCL and CTCL. The significance of this study lies in its potential to help patients achieve disease control, making them eligible for stem cell transplantation.
The research, published in lood Advances025, involved treating 38 patients with the drug duo, monitoring outcomes such as tumor reduction, survival rates, and side effects. Results showed that 61% of patients experienced a reduction or elimination of cancer, with nearly half (47%) having no detectable disease. Importantly, 11 patients subsequently underwent stem cell transplants.
Notably, among patients with the nodal T-follicular helper cell lymphoma subtype, an impressive 82% responded positively to the treatment. The side effects were manageable, though there was one fatality related to treatment complications.
Dr. Salvia Jain, a senior author, emphasized that the study’s outcomes support the use of duvelisib and romidepsin as a safe and effective option. The researchers hope this will lead to better access through insurance coverage and regulatory approval. Future research aims to identify markers that predict response or resistance to personalize treatment and improve outcomes.
This breakthrough offers new hope for patients with difficult-to-treat T-cell lymphomas, paving the way for improved therapeutic strategies and increased chances for successful stem cell transplants.
Source: https://medicalxpress.com/news/2025-07-drug-combination-effective-cell-lymphoma.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Eight-Month-Old Infants Demonstrate Adaptive Learning Capabilities
New research shows that eight-month-old babies can flexibly adapt their learning styles to environmental changes, indicating early cognitive maturity and active engagement in learning processes.
Rising Trends in Prenatal Care Among Pregnant Women in Australia
Australia sees a rise in early prenatal care among expectant mothers, coupled with demographic shifts and evolving birth practices, according to the latest AIHW report for 2023.
US Reports Over 1,000 Cases of Measles Amid Multiple State Outbreaks
The United States has reported over 1,000 measles cases across 11 states in 2025, highlighting the resurgence of this preventable disease due to declining vaccination rates and active outbreaks in multiple regions.
Early Detection of Alzheimer's Disease Using Brain and Blood Biomarkers in Middle Age
New research shows that Alzheimer's disease biomarkers can be detected in the brain and blood during middle age, paving the way for earlier diagnosis and intervention strategies. This breakthrough could transform how the disease is screened and managed in the future.